Literature DB >> 10865839

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction.

Y Sato1, S Kanno, N Oda, M Abe, M Ito, K Shitara, M Shibuya.   

Abstract

The properties of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF in human umbilical vein endothelial cells (HUVECs) were investigated by using two newly developed blocking monoclonal antibodies (mAbs) against Flt-1 and KDR. VEGF stimulated the expression of transcription factor Ets-1 as well as matrix metalloproteinase-1 (MMP-1) and Flt-1 in HUVECs. The KDR/Flt-1 heterodimer and the KDR homodimer mediate the expression of Ets-1, MMP-1, and Flt-1. VEGF also stimulated DNA synthesis and migration of HUVECs. DNA synthesis is mediated by the same signaling system as the expression of Ets-1. In contrast, cell migration is regulated by two distinct signaling systems. The Flt-1 homodimer is required for actin reorganization. The KDR/Flt-1 heterodimer and the KDR homodimer are required for the assembly of vinculin in focal adhesion plaque by regulating the phosphorylation of focal adhesion kinase (FAK) and paxillin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10865839     DOI: 10.1111/j.1749-6632.2000.tb06314.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  31 in total

Review 1.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

3.  Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration.

Authors:  Guido Beldi; Yan Wu; Xiaofeng Sun; Masato Imai; Keiichi Enjyoji; Eva Csizmadia; Daniel Candinas; Laurie Erb; Simon C Robson
Journal:  Gastroenterology       Date:  2008-07-31       Impact factor: 22.682

4.  Feedback Mechanisms Regulate Ets Variant 2 (Etv2) Gene Expression and Hematoendothelial Lineages.

Authors:  Naoko Koyano-Nakagawa; Xiaozhong Shi; Tara L Rasmussen; Satyabrata Das; Camille A Walter; Daniel J Garry
Journal:  J Biol Chem       Date:  2015-09-22       Impact factor: 5.157

Review 5.  VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.

Authors:  Yihai Cao
Journal:  Nat Rev Endocrinol       Date:  2014-07-22       Impact factor: 43.330

6.  Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2.

Authors:  Srimathi Srinivasan; Rosana D Meyer; Ricardo Lugo; Nader Rahimi
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

7.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 8.  Integrin and growth factor receptor alliance in angiogenesis.

Authors:  Payaningal R Somanath; Alieta Ciocea; Tatiana V Byzova
Journal:  Cell Biochem Biophys       Date:  2008-12-02       Impact factor: 2.194

9.  Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma.

Authors:  Tina Mukherjee; Anupam Kumar; Meera Mathur; Tushar Kant Chattopadhyay; Ranju Ralhan
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-08       Impact factor: 4.553

10.  Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis.

Authors:  Kenji Matsushita; Munekazu Yamakuchi; Craig N Morrell; Michitaka Ozaki; Brian O'Rourke; Kaikobad Irani; Charles J Lowenstein
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.